miglustat has been researched along with glycogen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, U; Butters, TD; Dwek, RA; Platt, FM | 1 |
| Do, HV; Feng, J; Frascella, M; Garcia, A; Gotschall, R; Khanna, R; Lun, Y; Martina, JA; Nair, A; Ponery, AS; Puertollano, R; Raben, N; Ralston, E; Schilling, A; Soska, R; Tuske, S; Valenzano, KJ; Valle, MCD; Xu, S | 1 |
| Blair, HA | 1 |
1 review(s) available for miglustat and glycogen
| Article | Year |
|---|---|
Cipaglucosidase Alfa: First Approval.
Topics: 1-Deoxynojirimycin; Adult; Enzyme Replacement Therapy; Glycogen; Glycogen Storage Disease Type II; Humans | 2023 |
2 other study(ies) available for miglustat and glycogen
| Article | Year |
|---|---|
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
Topics: 1-Deoxynojirimycin; Animals; Carbon Radioisotopes; Cell Division; Disaccharidases; Enzyme Inhibitors; Female; Glycogen; Glycosphingolipids; Humans; Liver; Lymphocytes; Mice; Mice, Inbred C57BL; Tissue Distribution | 2000 |
Improved efficacy of a next-generation ERT in murine Pompe disease.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Disease Models, Animal; Enzyme Replacement Therapy; Female; Glycogen; Glycogen Storage Disease Type II; Humans; Lysosomes; Male; Mannosephosphates; Mice; Mice, Knockout; Muscle, Skeletal; Rats; Rats, Sprague-Dawley | 2019 |